CER-1236

Product Description

CER-1236 is designed to elicit multiple functions via its TIM-4 phagocytic receptor together with innate and adaptive intracellular signaling domains. CER-1236 T cells demonstrate target-dependent phagocytic function and induce transcriptional signatures of key regulators responsible for phagocytic recognition and uptake, along with cytotoxic mediators. Pre-clinical models of mantle cell lymphoma (MCL) and EGFR mutation-positive non-small cell lung cancer (NSCLC) demonstrate collaborative innate-adaptive anti-tumor immune responses both in vitro and in vivo. Treatment with BTK (MCL) and EGFR (NSCLC) inhibitors increased target ligand, conditionally driving CER-1236 function to augment anti-tumor responses. We also show that activated CER-1236 T cells exhibit superior cross-presentation ability compared with conventional T cells, triggering E7-specific TCR T responses in an HLA class I- and TLR-2-dependent manner, thereby overcoming the limited antigen presentation capacity of conventional T cells. Therefore, CER-1236 T cells have the potential to achieve tumor control by eliciting both direct cytotoxic effects and indirect-mediated cross-priming. (Sourced from: https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(23)00264-2)

Mechanisms of Action: CAR-T,TIM4

Novel Mechanism: Yes

Modality: CAR-T

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CERo Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None